D ementia is a loss of mental functioning, including memory loss that is severe enough to interfere with daily functioning. Of dementia subtypes, Alzheimer's disease (AD) is the most common. However, there are many other causes of dementia. In this issue, we focus on one of the "related" degenerative dementias, frontotemporal dementia (FTD). We have multiple manuscripts from world authorities on this condition. Most of this work is directed at diagnosis and management of individuals with FTD. Recruitment of manuscripts for this focused issue was done in association with the Association for Frontotemporal Dementias (AFTD, http://www.ftd-picks.org/). Symptoms of FTD differ from those of AD because FTD patients experience more difficulty with language (aphasia) and more behavioral and early dysexecutive features.
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Hallam and his colleagues discuss the clinical presentation of prodromal FTD. This is an interesting manuscript that addresses the issues of diagnostic inaccuracies. It presents the current state of research in this area and identifies gaps in the literature and guiding future research. They determined that the prodromal stage of FTD is characterized by both cognitive (executive dysfunction, with associated memory recall impairment) and behavioral features. As prodromal symptoms overlap with other dementia subtypes, Hallam et al conclude that diagnostic accuracy for FTD will improve by considering both cognitive and behavioral features.
Oscher et al examine the Mini-Mental State Examination (MMSE) in the behavioral variant FTD and primary progressive aphasia. Retrospective data from 71 FTD patients were analyzed. They show that FTD patients with the behavioral FTD variant had a change in MMSE score over time that correlated with changes in their activities in daily living. In contrast, FTD patients with primarily language disturbance's MMSE scores showed greater declines over time than their activities of daily living scale scores. Because the MMSE is heavily language based, their results suggest that the MMSE score parallels functional impairment in behavioral forms of FTD but overestimates dementia severity in primary progressive aphasia FTD.
Rabinovici and colleagues compared MRI atrophy patterns in autopsy-proven AD and frontotemporal lobar degeneration to better define their anatomic distinctions. They retrospectively applied voxelbased-morphometry to the earliest MRIs of autopsyproven Alzheimer's disease, FTD and control cases. Compared with FTD, Alzheimer's disease patients had decreased gray matter in posterior parietal and occipital cortex, whereas FTD patients had atrophy in the anterior cingulate, frontal insula, subcallosal gyrus, and striatum. Compared with controls, AD patients showed gray matter loss in posterior temporoparietal and occipital cortex; FTD patients showed atrophy in medial prefrontal and medial temporal cortex, insula, hippocampus, and amygdala. Both showed atrophy in dorsolateral and orbital prefrontal cortex and medial and lateral temporal cortex. These findings support the growing body of evidence suggesting that AD and FTD are anatomically distinct.
Caselli et al describe the medical management of individuals with FTD. There are no FDA-approved medications for FTD, so all management recommendations are off-label. Caselli et al discuss six areas of pharmacotherapeutic intervention including prevention, intellectual decline, behavioral problems, sleep disorders, other associated disorders, and the approach to patients with abrupt decline. In addition to pharmacotherapy, Caselli et al stress the importance of also addressing important lifestyle safety-related issues.
Grinberg et al describe a multidisciplinary day program specialized for FTD. This program showed an immediate positive outcome for caregiver burden for an underserved group of caregivers and improved behavioral management. Massimo et al also address patient care and management of FTD and discuss clinical features and biomarkers. The diagnosis of an FTD patient includes a detailed cognitive exam, clinical testing, and neuroimaging techniques. They stress that medical treatment of FTD is symptomatic management; interventions do not currently affect the disease course. They agree that nonpharmacologic management such as behavioral interventions and environmental engineering are also efficacious in optimizing quality of life (QOL).
In the final FTD article, Goldman et al describe the genetics of FTD. Up to 40% of FTD cases have a positive family history. There are four disease-causing FTD genes: microtubule associated protein tau (MAPT), progranulin (PGRN), valosin-containing protein (VCP), and charged multivesicular body protein 2B (CHMP2B). Most are PGRN or MAPT gene mutations. These are associated with significant phenotypic variability.
Frank explores links between anticipatory grief, ambiguous loss, and principal barriers that family members face as dementia caregivers across the state of Indiana. This is the first study of anticipatory grief as an actual barrier to the task of caregiving.
She analyzes 353 open-ended survey responses in this article by drawing parallels between caregiver responses and the Marwit-Meuser Caregiver Grief Inventory subscales, and illustrates that the fundamental barrier experienced by current Alzheimer's caregivers appears to be a combination of anticipatory grief and ambiguous loss rather than hands-on care issues.
Ready and Ott study QOL reporting of people with mild to moderate AD. Using the Cornell Brown Scale (CBS) for QOL in dementia, they question if using aggregated patient and informant QOL reports would provide a broader perspective on QOL relative to using patient or informant reports in isolation. Patients with mild cognitive impairment and mild to moderate AD can provide information about their QOL. Aggregated CBS scores were hypothesized to correlate more strongly with both patient and informant perspectives of patient memory, function, and neuropsychiatric symptoms than unaggregated measures. They found that aggregated CBS scores reflected a blend of patient and informant perspectives on patient function. This study contributes to a growing line of research that recommends integrating patient and informant perspectives to achieve the most complete assessment of QOL.
A new dementia subtype, diffuse neurofibrillary tangles with calcification (DNTC), is described by Nanda and others. Until now this has been reported almost exclusively from Japan. Significant pathological advances in this decade have established DNTC as a distinct entity. Although initially the diagnosis was neuropathologic, increasing knowledge about DNTC has made it possible for a clinical diagnosis to be made. They report a clinical case of DNTC in a Caucasian American. The diagnosis of DNTC was based on his atypical senile dementia, anomia, apathy and parkinsonian features, normal serum biochemistry, and evidence of basal ganglia and cerebellar calcification with predominant temporal lobe atrophy on neuroimaging. They state that this is the first clinical description of DNTC from the United States.
